| CAR T cells produced in vivo to treat cardiac injury JG Rurik, I Tombácz, A Yadegari, PO Méndez Fernández, SV Shewale, ... Science 375 (6576), 91-96, 2022 | 806 | 2022 |
| Targeting cardiac fibrosis with engineered T cells H Aghajanian, T Kimura, JG Rurik, AS Hancock, MS Leibowitz, L Li, ... Nature 573 (7774), 430-433, 2019 | 606 | 2019 |
| Immune cells and immunotherapy for cardiac injury and repair JG Rurik, H Aghajanian, JA Epstein Circulation research 128 (11), 1766-1779, 2021 | 180 | 2021 |
| CAR-based therapies: opportunities for immuno-medicine beyond cancer H Aghajanian, JG Rurik, JA Epstein Nature metabolism 4 (2), 163-169, 2022 | 95 | 2022 |
| Tissue-specific Grb10/Ddc insulator drives allelic architecture for cardiac development AM Juan, YH Foong, JL Thorvaldsen, Y Lan, NA Leu, JG Rurik, L Li, ... Molecular cell 82 (19), 3613-3631. e7, 2022 | 21 | 2022 |
| Pbx4 is required for the temporal onset of zebrafish myocardial differentiation RM Kao, JG Rurik, HF Gist III, XR Dong, MW Majesky, L Maves Journal of developmental biology 3 (4), 93-111, 2015 | 20 | 2015 |
| Proteolytic degradation of regulator of G protein signaling 2 facilitates temporal regulation of Gq/11 signaling and vascular contraction SM Kanai, AJ Edwards, JG Rurik, P Osei-Owusu, KJ Blumer Journal of Biological Chemistry 292 (47), 19266-19278, 2017 | 15 | 2017 |
| Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System In Vivo to Treat Heart Disease JG Rurik, JA Epstein DNA and Cell Biology 41 (6), 539-543, 2022 | 5 | 2022 |
| Non-viral vectors for chimeric antigen receptor immunotherapy US Tretbar, JG Rurik, EH Rustad, D Sürün, U Köhl, J Olweus, F Buchholz, ... Nature Reviews Methods Primers 4 (1), 74, 2024 | 2 | 2024 |
| In vivo targeting of Fibrosis by anti-CD5-targeted FAP-CAR T mRNA-LNP H Parhiz, D Weissman, J Epstein, I Tombacz, J Rurik, H Aghajanian US Patent App. 17/938,816, 2023 | 1 | 2023 |
| IN VIVO ANTI-FAP CAR T CELLS THAT TARGET FIBROGENIC HEPATIC STELLATE CELL SUBSETS AMELIORATE MURINE (MASH) LIVER FIBROSIS C Yashaswini, B Cogliati, T Qin, J Rurik, T Williamson, T Papp, K Li, ... HEPATOLOGY 80, S1541-S1542, 2024 | | 2024 |
| TARGETING PATHOGENIC FIBROBLASTS WITH ENGINEERED T CELLS J Rurik University of Pennsylvania, 2023 | | 2023 |
| Assaying fibroblast activation protein (FAP) expression in vivo and in vitro for possible targeting with chimeric antigen receptor (CAR) T cells PO Méndez Fernández, JG Rurik, H Aghajanian, JA Epstein The FASEB Journal 36, 2022 | | 2022 |